SSY Group Limited (02005.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenHKD 2.77

From 52W high−14.83%

Volume4.19M

Market capHKD 7.97B

P/E (TTM)15.5x

P/S (TTM)1.8x

Div yield3.15%

Key dataSep 18, 2026

Open

HKD 2.77

From 52W high

−14.83%

Volume

4.19M

Market cap

HKD 7.97B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

9.8x

P/E (TTM)

15.5x

RSI (14)

59.4

MomentumView details →

1D Return

−2.00%

YTD Return

−4.59%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

15.5x

EV/EBITDA

9.8x

EV/Sales

2.4x

P/S (TTM)

1.8x

P/B (TTM)

1.0x

ProfitabilityView details →

Gross Margin

40.03%

Net Margin

11.59%

EBITDA Margin

24.14%

ROE (TTM)

6.50%

ROA (TTM)

3.77%

Asset Turnover

0.33x

GrowthView details →

Revenue YoY

−4.42%

EPS YoY

−23.03%

FCF YoY

+851.59%

Revenue CAGR 3Y

−13.49%

EPS CAGR 3Y

−25.05%

EBITDA YoY

−15.45%

MomentumView details →

1D Return

−2.00%

YTD Return

−4.59%

1Y Return

−8.78%

RSI (14)

59.4

vs 50D SMA

+6.90%

vs 200D SMA

+4.01%

Capital & dividendView details →

Debt/Equity

0.52x

Current Ratio

1.87x

Quick Ratio

1.43x

Div Yield

3.15%

Div Rate

HKD 0.08

Div Growth 1Y

−41.38%

EarningsView details →

EPS (Actual)

HKD 0.11

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

−0.09%

Financials snapshotView financials →

Revenue (TTM)

8.96B

Net Income (TTM)

1.17B

Op. CF (TTM)

1.38B

Next earningsMar 26, 2027 →

Latest newsMore news →

Shijiazhuang No.4 Pharmaceutical obtained production registration approval from China's National Medical Products Administration for its Letermovir Injection (12ml:240mg), a Category 4 chemical drug deemed to have passed consistency evaluation, used to prevent cytomegalovirus infection and disease in adult CMV-seropositive recipients of allogeneic hematopoietic stem cell transplants.10d ago

SSY Group announced that its Diltiazem Hydrochloride Tablets (30mg) received approval from China's National Medical Products Administration for passing the consistency evaluation of generic drug quality and efficacy, making it the third domestic company to obtain such approval.18d ago

Similar companies

华北制药600812.SH 太极集团600129.SH 上海谊众688091.SH 汇宇制药-W688553.SH 鲁抗医药600789.SH 复旦张江688505.SH Find similar companies →

Latest newsMore news →

Shijiazhuang No.4 Pharmaceutical obtained production registration approval from China's National Medical Products Administration for its Letermovir Injection (12ml:240mg), a Category 4 chemical drug deemed to have passed consistency evaluation, used to prevent cytomegalovirus infection and disease in adult CMV-seropositive recipients of allogeneic hematopoietic stem cell transplants.10d ago SSY Group announced that its Diltiazem Hydrochloride Tablets (30mg) received approval from China's National Medical Products Administration for passing the consistency evaluation of generic drug quality and efficacy, making it the third domestic company to obtain such approval.18d ago SSY Group Limited received a drug production registration certificate from China's National Medical Products Administration for its Vitamin K1 injection (1ml:10mg), a Class 3 chemical drug deemed equivalent to generic consistency evaluation.31d ago